Asia-pacific age- related macular degeneration (AMD) market is projected to register a CAGR of 7.2% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2021 and the forecast period is 2022 to 2029.
Market Segmentation:
Asia-Pacific Age- Related Macular Degeneration (AMD) Market, By Types (Dry AMD and Wet AMD), End User(Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare, and Others) and Distribution Channel(Direct Tender and Retail Sales) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the Asia-Pacific age-related macular degeneration (AMD) market are:
Growing geriatric population
Growing prevalence of macular degeneration
Market Players:
The key market players for Asia-Pacific age-related macular degeneration (AMD) market are listed below:
Astellas Pharma
Ionis Pharmaceutics
Bayer AG
Novartis AG
Johnson and Johnson
TABLE OF CONTENT
TABLE OF CONTENTS
1 INTRODUCTION 26
1.1 OBJECTIVES OF THE STUDY 26
1.2 MARKET DEFINITION 26
1.3 OVERVIEW OF ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET 26
1.4 LIMITATIONS 28
1.5 MARKETS COVERED 28
2 MARKET SEGMENTATION 31
2.1 MARKETS COVERED 31
2.2 GEOGRAPHICAL SCOPE 32
2.3 YEARS CONSIDERED FOR THE STUDY 33
2.4 CURRENCY AND PRICING 33
2.5 DBMR TRIPOD DATA VALIDATION MODEL 34
2.6 MULTIVARIATE MODELLING 37
2.7 TYPE LIFELINE CURVE 37
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 38
2.9 DBMR MARKET POSITION GRID 39
2.10 MARKET END USER COVERAGE GRID 40
2.11 VENDOR SHARE ANALYSIS 41
2.12 SECONDARY SOURCES 42
2.13 ASSUMPTIONS 42
3 EXECUTIVE SUMMARY 43
4 PREMIUM INSIGHTS 46
4.1 PESTEL 47
4.2 PORTER'S FIVE FORCES MODEL 48
5 REGULATORY FRAMEWORK 49
6 MARKET OVERVIEW 52
6.1 DRIVERS 54
6.1.1 RISING PREVALENCE OF AGE-RELATED MACULAR DEGENERATION 54
6.1.2 INCREASING GERIATRIC POPULATION 54
6.1.3 INCREASE IN PIPELINE PRODUCTS 55
6.1.4 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYERS 56
6.2 RESTRAINTS 56
6.2.1 HIGH COST OF TREATMENT AND PROCEDURES 56
6.2.2 LACK OF ENOUGH QUALIFIED PROFESSIONALS 57
6.3 OPPORTUNITIES 58
6.3.1 INCREASING RESEARCH AND DEVELOPMENT 58
6.3.2 INCREASE IN AWARENESS AND TREATMENT-SEEKING RATE OF AMD 58
6.3.3 EMERGING REIMBURSEMENT POLICIES FOR THE TREATMENT 59
6.3.4 INCREASING PRODUCT APPROVAL FOR AGE-RELATED MACULAR DEGENERATION (AMD) 59
6.4 CHALLENGES 60
6.4.1 LIMITED ACCESS TO TREATMENT 60
6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR PRODUCTS 60
7 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE 61
7.1 OVERVIEW 62
7.2 DRY AMD 65
7.3 WET AMD 65
7.3.1 MEDICATIONS 66
7.3.2 ANTI-VEGF THERAPY 67
7.3.3 GENE THERAPY 67
7.3.4 SURGERY 67
8 ASIA PACIFIC AGE- RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER 68
8.1 OVERVIEW 69
8.2 HOSPITALS 72
8.3 SPECIALTY CLINICS 72
8.4 AMBULATORY SURGICAL CENTERS 73
8.5 HOME HEALTHCARE 74
8.6 OTHERS 75
9 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL 76
9.1 OVERVIEW 77
9.2 RETAIL SALES 81
9.2.1 HOSPITAL PHARMACIES 82
9.2.2 RETAIL PHARMACIES 82
9.2.3 OTHERS 82
9.3 DIRECT TENDER 82
10 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION 83
10.1 ASIA-PACIFIC 84
10.1.1 CHINA 91
10.1.2 JAPAN 93
10.1.3 INDIA 95
10.1.4 SOUTH KOREA 97
10.1.5 AUSTRALIA 99
10.1.6 SINGAPORE 101
10.1.7 THAILAND 103
10.1.8 INDONESIA 105
10.1.9 PHILIPPINES 107
10.1.10 MALAYSIA 109
10.1.11 VIETNAM 111
10.1.12 REST OF ASIA-PACIFIC 113
11 ASIA PACIFIC AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: COMPANY LANDSCAPE 114
11.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 114
12 SWOT ANALYSIS 115
13 COMPANY PROFILE 116
13.1 NOVARTIS AG 116
13.1.1 COMPANY SNAPSHOT 116
13.1.2 REVENUE ANALYSIS 116
13.1.3 COMPANY SHARE ANALYSIS 117
13.1.4 PRODUCT PORTFOLIO 117
13.1.5 RECENT DEVELOPMENT 117
13.1.5.1 AGREEMENT 117
13.2 GENENTECH, INC. 118
13.2.1 COMPANY SNAPSHOT 118
13.2.2 COMPANY SHARE ANALYSIS 118
13.2.3 PRODUCT PORTFOLIO 119
13.2.4 RECENT DEVELOPMENT 119
13.3 BAYER AG 120
13.3.1 COMPANY SNAPSHOT 120
13.3.2 REVENUE ANALYSIS 120
13.3.3 COMPANY SHARE ANALYSIS 121
13.3.4 PRODUCT PORTFOLIO 121
13.3.5 RECENT DEVELOPMENT 121
13.4 ADVERUM BIOTECHNOLOGIES, INC. 122
13.4.1 COMPANY SNAPSHOT 122
13.4.2 REVENUE ANALYSIS 122
13.4.3 PRODUCT PORTFOLIO 122
13.4.4 RECENT DEVELOPMENT 123
13.5 ASTELLAS PHARMA INC. 124
13.5.1 COMPANY SNAPSHOT 124
13.5.2 REVENUE ANALYSIS 124
13.5.3 PRODUCT PORTFOLIO 125
13.5.4 RECENT DEVELOPMENT 125
13.6 GRAYBUG VISION INC. 126
13.6.1 COMPANY SNAPSHOT 126
13.6.2 REVENUE ANALYSIS 126
13.6.3 PRODUCT PORTFOLIO 126
13.6.4 RECENT DEVELOPMENT 127
13.7 GENSIGHT BIOLOGICS 128
13.7.1 COMPANY SNAPSHOT 128
13.7.2 REVENUE ANALYSIS 128
13.7.3 PRODUCT PORTFOLIO 129
13.7.4 RECENT DEVELOPMENTS 129
13.7.4.1 EVENT 129
13.7.4.2 AWARD 129
13.8 IONIS PHARMACEUTICALS 130
13.8.1 COMPANY SNAPSHOT 130
13.8.2 REVENUE ANALYSIS 130
13.8.3 PRODUCT PORTFOLIO 131
13.8.4 RECENT DEVELOPMENT 131
13.8.4.1 EVENT 131
13.9 IVERIC BIO 132
13.9.1 COMPANY SNAPSHOT 132
13.9.2 PRODUCT PORTFOLIO 132
13.9.3 RECENT DEVELOPMENT 132
13.10 JOHNSON &JOHNSON SERVICES, INC. 133
13.10.1 COMPANY SNAPSHOT 133
13.10.2 REVENUE ANALYSIS 133
13.10.3 PRODUCT PORTFOLIO 134
13.10.4 RECENT DEVELOPMENT 134
13.10.4.1 COLLABORATION 134
13.11 KODIAK SCIENCES INC. 135
13.11.1 COMPANY SNAPSHOT 135
13.11.2 PRODUCT PORTFOLIO 135
13.11.3 RECENT DEVELOPMENT 135
13.12 MEIRAGTX LIMITED 136
13.12.1 COMPANY SNAPSHOT 136
13.12.2 PRODUCT PORTFOLIO 136
13.12.3 RECENT DEVELOPMENTS 136
13.12.3.1 EVENTS 136
13.12.3.2 AWARD 137
13.12.3.3 COLLABORATION 137
13.13 OCUGEN INC. 138
13.13.1 COMPANY SNAPSHOT 138
13.13.2 PRODUCT PORTFOLIO 138
13.13.3 RECENT DEVELOPMENTS 138
13.13.3.1 INVESTMENT 138
13.13.3.2 CLINICAL TRIAL 139
13.14 PIXIUM VISION 140
13.14.1 COMPANY SNAPSHOT 140
13.14.2 REVENUE ANALYSIS 140
13.14.3 PRODUCT PORTFOLIO 140
13.14.4 RECENT DEVELOPMENT 141
13.14.4.1 AWARD 141
13.15 REGENXBIO INC. 142
13.15.1 COMPANY SNAPSHOT 142
13.15.2 PRODUCT PORTFOLIO 142
13.15.3 RECENT DEVELOPMENTS 142
13.15.3.1 EVENT 142
13.15.3.2 COLLABORATION 143
13.15.3.3 CERTIFICATION 143
14 QUESTIONNAIRE 144
15 RELATED REPORTS 147
Segmentation
Short Description
Asia-Pacific Age-Related Macular Degeneration (AMD) Disease Market, By Type (Dry AMD and Wet AMD) End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare and Others) Distribution Channel (Direct Tender and Retail Sales) Country (Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific) Industry Trends and Forecast to 2029
Market Definition:
Age-related macular degeneration (AMD) is an eye disease that can cause damage to the macula part of the eye that controls sharp and straight-ahead vision. This leads to blur central vision. Vision loss that can be caused by abnormal blood vessel growth. Macular degeneration is more common in aging people. The diagnosis of disease is possible at various stages and number of genetic testing and retinal imaging are some of the techniques for the detection of disease. The diagnosis of the disease is conducted mainly by optical imaging techniques and other standard process.
Age-related macular degeneration (AMD) can cause damage to the macula part of the eye. This leads to blur central vision. It can cause irreversible blindness and is the leading cause of visual impairment in the elderly people.The diagnosis and treatment of age-related macular degeneration (AMD) disease consist of various techniques that allow diagnosis of disease after the approval of the product. The treatment for the disease is recently approved which support the market growth. However, these treatments are expensive and not available to all patients in many countries.
Market Segmentation:
Asia-Pacific age-related macular degeneration (AMD) disease market is categorized into three notable segments such as type, end user, and distribution channel.
On the basis of type, the Asia-Pacific age-related macular degeneration (AMD) disease market is segmented into dry AMD and wet AMD
On the basis of end user, the Asia-Pacific age-related macular degeneration (AMD) disease market is segmented into hospitals, specialty clinics, ambulatory surgical centers, home healthcare and others
On the basis of distribution channel, the Asia-Pacific age-related macular degeneration (AMD) disease market is segmented into direct tenders and retail sales
Market Players
The key market players for Asia-Pacific age-related macular degeneration (AMD) disease Market are listed below:
Novartis AG
Bayer AG
Astellas Pharma Inc.
Ionis Pharmaceutics
Johnson & Johnson Services, Inc.
Methodology
Why Choose Us
24 * 7 Access to Analyst :
Get your pre and post sales queries resolved by our Subject matter experts.
Customization :
We will assist you to customize the report to fit your research needs.
Assured Quality :
Our prime focus is to provide qualitative and accurate data.
Free sample report :
Feel free to order a sample report before purchase.
Security :
Your personal and confidential information is safe and secured.
